Literature DB >> 2754197

Prediction of recurrence in the treatment of Dupuytren's disease: evaluation of a histologic classification.

J J Rombouts1, H Noël, Y Legrain, E Munting.   

Abstract

Histologic staging of Dupuytren's lesions into three types is proposed: a proliferative type with high cellularity and mitosis, a fibrocellular type characterized by the presence of a reticulin network, and a fibrous type with few cells. Sixty-three patients (77 hands) who had selective fasciectomy as a primary procedure and whose histologic specimen was available were clinically reviewed for disease recurrence and extension. Twenty-two hands (29%) were free of disease; twenty-five (32%) were free from recurrence but showed an extension, and thirty (39%) had a recurrence. This histologic classification seems to have a prognostic value because the recurrence rate is higher in type I (70%) and lower in type III (18%). The risk of extension did not correlate with the histologic type.

Entities:  

Mesh:

Year:  1989        PMID: 2754197     DOI: 10.1016/0363-5023(89)90183-4

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  6 in total

1.  A systematic review of outcomes of fasciotomy, aponeurotomy, and collagenase treatments for Dupuytren's contracture.

Authors:  Neal C Chen; Ramesh C Srinivasan; Melissa J Shauver; Kevin C Chung
Journal:  Hand (N Y)       Date:  2011-03-01

2.  Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic target.

Authors:  Liaquat S Verjee; Jennifer S N Verhoekx; James K K Chan; Thomas Krausgruber; Vicky Nicolaidou; David Izadi; Dominique Davidson; Marc Feldmann; Kim S Midwood; Jagdeep Nanchahal
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

Review 3.  Dupuytren's Disease-Etiology and Treatment.

Authors:  Mike Ruettermann; Robert Michael Hermann; Karl Khatib-Chahidi; Paul M N Werker
Journal:  Dtsch Arztebl Int       Date:  2021-11-19       Impact factor: 8.251

4.  Beta-catenin overexpression in Dupuytren's disease is unrelated to disease recurrence.

Authors:  Ilse Degreef; Luc De Smet; Raf Sciot; Jean-Jacques Cassiman; Sabine Tejpar
Journal:  Clin Orthop Relat Res       Date:  2008-10-29       Impact factor: 4.176

5.  Seven-year clinical outcomes after collagenase injection in patients with Dupuytren's disease: A prospective study.

Authors:  Rocco De Vitis; Marco Passiatore; Andrea Perna; Silvia Careri; Vitale Cilli; Giuseppe Taccardo
Journal:  J Orthop       Date:  2020-03-29

Review 6.  Systematic review of non-surgical treatments for early dupuytren's disease.

Authors:  Catherine Ball; David Izadi; Liaquat Suleman Verjee; James Chan; Jagdeep Nanchahal
Journal:  BMC Musculoskelet Disord       Date:  2016-08-15       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.